Axiron net sales, as announced by Eli Lilly , for the quarter ended 30 June 2014 totalled USD 47 ..... single-product focus, and limited control over sales under the Eli Lilly agreement, and reiterate our very high uncertainty rating
July 24 (Reuters) - Eli Lilly and Co's quarterly revenue plunged due to generic competition for its Cymbalta depression drug and its Evista osteoporosis treatment, but cost controls helped earnings...
July 24 (Reuters) - Eli Lilly and Co : * CFO, in conference call with investors, says company would not pursue tax inversions as "primary driver" of any
Eli Lilly (NYSE: LLY ) Q2 results : Total Revenue: $4,935.6M (-16.4%), Animal Health: $601.2M (+5.7%); COGS
Eli Lilly reported second-quarter results that ran slightly ahead of both our expectations and those of consensus. While Lilly is facing
July 24 (Reuters) - Eli Lilly and Co's quarterly revenue plunged due to generic competition for its Cymbalta depression drug and its Evista osteoporosis treatment, but overall results beat forecasts, helped by cost controls.
Eli Lilly (NYSE: LLY ): Q2 EPS of $0.68 beats by $0.03 . Revenue of $4.94B (-16.7% Y/Y) beats by $60M . Press Release Post your comment!
By WhisperNumber : Eli Lilly and Company (NYSE: LLY ) is expected to report earnings on Thursday ..... the analysts' estimate and showing no confidence from investors. Eli Lilly has a 74% positive surprise history (having topped the whisper in
Many industry observers are watching the IP-related dispute between Eli Lilly ( LLY -0.4% ) and the Canadian government. Several years ago, Canadian courts invalidated Lilly's patents on its ADHD drug
A dataset analysis by researchers at Eli Lilly (NYSE: LLY ) evaluating the relationship between cognitive and functional impairment in patients with mild Alzheimer's disease